Oxygen Therapy Business Insurance UK | Specialist Broker
Why has UK oxygen therapy business insurance changed materially in 2026?
For most of the past decade, UK oxygen therapy operated in two distinct lanes that rarely interacted. On one side, clinical hyperbaric oxygen therapy (HBOT) — provided in NHS-contracted multiplace chamber centres for conditions including decompression illness, carbon monoxide poisoning, and diabetic foot ulcers, governed by a mature service specification framework and a small specialist insurance market. On the other side, ambient oxygen and "oxygen bar" hospitality offerings, treated by underwriters as adjacent to spa, beauty, or wellness services. The two lanes have collapsed into one expanding, contested middle ground — and the insurance market has reset accordingly.
Three specific triggers drove the 2026 underwriting transformation. First, the well-publicised 31 January 2025 fatal fire inside a monoplace hyperbaric chamber at the Oxford Center in Troy, Michigan, in which a five-year-old boy was killed and his mother injured. While that incident occurred in the US, it is the working international precedent for hyperbaric fire risk and reset every UK underwriter's view of the catastrophic exposure attached to oxygen-enriched pressurised environments. Second, the rapid proliferation of mild hyperbaric oxygen therapy (mHBOT) wellness centres operating soft-shell single-place chambers — a segment that didn't meaningfully exist five years ago and that operates in a documented MHRA regulatory grey zone. Third, the January 2025 update to NHS England's clinical HBOT service specification, which tightened standards across the NHS-contracted provider network and indirectly raised expectations on the wider UK sector.
The downstream effect on UK oxygen therapy underwriting in 2026 has been: catastrophic-event PL scope tightened with explicit fire and explosion treatment; equipment failure cover increasingly conditional on documented PUWER and DSEAR compliance; PI scope expanded to address barotrauma, oxygen toxicity, and contraindication-screening claims; and proposal-stage demand for clear declaration of which oxygen modality the business operates (clinical HBOT, mHBOT, ambient oxygen / oxygen bar, supplemental oxygen for athletes). Generic alternative therapy packages built for the pre-2025 market are no longer adequate for the post-2025 risk profile.
This guide is the definitive 2026 UK oxygen therapy business insurance article — built around the dual-modality risk landscape, the eight distinct claim-driving exposures, the cover architecture that responds, and the operational documentation that makes both regulatory compliance and claim defence possible. It complements our alternative therapies business insurance product page and sits within the wider alternative therapies cluster including IV drip therapy, red light therapy, cold plunge therapy, cryotherapy, float therapy, and ADHD clinic services.
Key facts at a glance
- The 31 January 2025 Troy, Michigan hyperbaric chamber fatality reset UK underwriting expectations — a five-year-old boy died and his mother was injured when a monoplace HBOT chamber ignited. The incident is the working international precedent for catastrophic hyperbaric fire risk and has tightened proposal-stage fire safety documentation expectations across UK underwriters.
- The MHRA does not classify hyperbaric chambers as medical devices when operated by non-healthcare workers — a documented regulatory gap that places the mHBOT wellness sector outside the strict device safety framework, exposing operators to elevated PL claim exposure and complicating CQC registration decisions.
- Oxygen-enriched environments accelerate fire spread dramatically — at the partial pressures used in clinical HBOT (typically 2–3 atmospheres absolute), the partial pressure of oxygen is approximately 11–14 times higher than atmospheric. Fire fatalities in the chamber are typically catastrophic and rapid.
- HBOT carries documented clinical risk that PI cover must address — barotrauma (auditory, pulmonary, sinus), oxygen toxicity (neurological seizures, pulmonary pneumonitis), arterial gas embolism, and pneumothorax are recognised complications even where treatment is conducted correctly. Screening and consent documentation is critical defence.
- UK oxygen therapy is governed by HSAW 1974, PUWER 1998, COSHH 2002, and DSEAR 2002 regardless of MHRA medical device status. DSEAR 2002 specifically applies because oxygen is classified as an oxidising substance creating explosive atmosphere risk. HSE prosecution exposure is real.
- 2026 UK oxygen therapy insurance premiums range from £1,200 for a single-chamber wellness operator to £75,000+ for multi-chamber clinical HBOT centres. The differential between modality types is larger than within any band — clinical HBOT pricing is 5–8× equivalent-turnover wellness operations.
- Insurance non-disclosure under the Insurance Act 2015 is the most preventable catastrophe — operating mHBOT under a wellness package without specifically declaring pressurised oxygen-enriched chamber operation leaves claims uninsured. Specific declaration at proposal is the only mitigation.
1. What's the difference between clinical HBOT and wellness mHBOT — and why does it matter?
The single most important distinction for UK oxygen therapy insurance is which modality the business operates. The risk profiles are different, the regulatory frameworks are different, and the cover architecture is different. Conflating them at proposal stage is the most common source of cover gaps we see when reviewing existing oxygen therapy policies.
Clinical HBOT (multiplace and hard-shell monoplace chambers)
Clinical hyperbaric oxygen therapy operates at 2.0–3.0 atmospheres absolute (ATA) using either large multiplace chambers (treating multiple patients with an attendant inside) or hard-shell single-place chambers. Treatment indications align broadly to the conditions specified in the NHS England service specification: decompression illness, arterial gas embolism, carbon monoxide poisoning, late radiation tissue injury, problem wounds, necrotising soft tissue infections, and others. Operators are typically NHS-contracted or operate alongside the NHS. Staffing typically includes a hyperbaric physician on site, chamber operator, and attendants. Chambers are pressure vessels regulated as such under the Pressure Equipment (Safety) Regulations 2016 and constructed to BS EN 14931 standards.
Wellness mHBOT (mild hyperbaric oxygen therapy, soft-shell chambers)
Mild hyperbaric oxygen therapy operates at lower pressures — typically 1.3–1.5 ATA — using soft-shell inflatable chambers. The wellness sector promotes mHBOT for general wellbeing, athletic recovery, anti-ageing, post-COVID recovery, and a range of off-label conditions. Clinical evidence for these uses is contested. UK regulatory position is complex: as noted by independent clinicians who have publicly engaged on the issue, the MHRA does not classify hyperbaric chambers as medical devices when operated by non-healthcare workers, which leaves mHBOT outside the strict medical device safety framework. CQC registration is required only where a "regulated activity" is being performed (typically only if a clinical treatment is being offered by a healthcare professional). The result is that many UK mHBOT wellness centres operate without the regulatory oversight applied to clinical HBOT — but the fire, equipment, and clinical risks are not proportionately reduced.
Ambient oxygen / oxygen bars
Ambient oxygen services deliver supplemental oxygen (typically 90–95% concentration via concentrator) through nasal cannula at atmospheric pressure. The fire risk profile is lower than HBOT (no pressurisation, no chamber atmosphere) but oxygen-enriched ambient air is still a powerful oxidiser and ignition sources must be controlled. Used in hospitality (oxygen bars), beauty (oxygen facials), and athletic recovery contexts.
Supplemental oxygen for athletes / portable oxygen
Athletic and recovery contexts in which supplemental oxygen is supplied during or after exercise. Cover sits within sports facility or studio insurance with specific oxygen handling declaration; the dominant risk is fire ignition rather than barotrauma or toxicity.
2. The 8 biggest oxygen therapy risks: summary table
The risks below are ranked by combined frequency, severity, and regulatory consequence under the post-2025 framework. Fire/explosion is the dominant catastrophic exposure and the reason oxygen therapy insurance is priced differently from comparable alternative therapy modalities. The risk pattern broadly parallels what we see in our sister cryotherapy business insurance guide for chamber-based treatment operations, with the oxidising-atmosphere dimension distinct to oxygen.
| Risk | Frequency | Severity | Primary Cover |
|---|---|---|---|
| Fire / explosion in oxygen-enriched environment | Rare — catastrophic when occurs | Catastrophic (£250k–£5m+ per incident) | PL, Property, Business Interruption |
| Barotrauma and decompression injury | Occasional | Medium-High (£15k–£80k typical) | Professional Indemnity / Medical Malpractice |
| Oxygen toxicity (neurological / pulmonary) | Rare but recognised | High (£40k–£250k+) | Professional Indemnity / PL |
| Equipment failure / PUWER breach | Common — varies by maintenance | Low-Medium (£2k–£40k typical) | PL, Equipment, Business Interruption |
| Inadequate clinical screening | Rising | Medium-High (£20k–£100k) | Professional Indemnity |
| MHRA medical device regulatory uncertainty | Ongoing structural | Variable — affects cover scope | PI scope review, EIL |
| HSE prosecution / DSEAR breach | Rare per business | Catastrophic (£150k+ fines, prison) | Legal Expenses, D&O |
| Insurance non-disclosure (IA 2015) | Common (often unnoticed) | Catastrophic (uninsured loss) | None — proposal stage only |
3. Risk 1: Fire and explosion — the dominant catastrophic exposure
Fire and Explosion — The Catastrophic Exposure
Oxygen is not flammable itself but is a powerful oxidiser that dramatically accelerates the ignition and burn rate of any combustible material it contacts. Inside a hyperbaric chamber operating at 2.0–3.0 ATA, the partial pressure of oxygen is approximately 11–14 times atmospheric, meaning that any ignition source — static electricity, electrical fault, friction spark, oil contamination on equipment, prohibited personal items (cosmetics, hair products, synthetic fabrics, electronic devices) — can cause rapid and total combustion. The 31 January 2025 Troy, Michigan fatal fire is the working international precedent: a monoplace chamber ignited with a child inside, the child died, and his mother standing beside the chamber suffered burn injuries to her arms. Fire incidents in the oxygen-enriched ambient environment of oxygen bars and oxygen facials are less catastrophic but still account for documented insurance claims and property damage.
The UK regulatory framework treats oxygen-enriched atmospheres as explosive atmospheres under DSEAR 2002. The Regulatory Reform (Fire Safety) Order 2005 places the duty for fire risk assessment on the responsible person at the premises. HSE guidance is extensive: HSE INDG408 on working with oxygen and OC 130/8 on hyperbaric chambers both apply. Operating without documented DSEAR risk assessment, zone classification, and explosion protection measures is itself a regulatory breach and a major underwriting red flag.
Documented DSEAR risk assessment per location including zone classification (Zone 0/1/2 for oxygen-enriched atmospheres); fire risk assessment per RR(FS)O 2005 with periodic review; ignition source elimination protocol (anti-static garments, prohibited items list, equipment intrinsically safe or certified for oxygen-enriched environments, oil-free maintenance); chamber interior fire-suppression where applicable (multiplace chambers); electrical installation to ATEX standards in oxygen-enriched zones; documented patient briefing and pre-treatment garment change procedure; emergency depressurisation procedure documented and rehearsed; smoke and heat detection appropriate to environment; fire-fighting equipment specifically rated for oxygen-fed fires; staff trained in fire response with documented drills; building insurance provider notified of chamber installation; landlord consent and lease compliance for chamber installations.
Public Liability with explicit fire and explosion treatment risk scope (generic alternative therapy PL may sub-limit or exclude oxygen-enriched atmosphere fire incidents); Property insurance with the chamber and oxygen storage installation specifically declared; Business Interruption covering the period of chamber and premises unavailability post-incident; Environmental Impairment Liability for any pollution from suppression water, oxygen leak, or smoke damage to neighbouring premises. Claim values are extreme — a chamber fire fatality can engage £1m–£5m+ in combined PL, property, BI, and legal costs. Specialist Lloyd's market placement is typically necessary for clinical HBOT centres; mainstream package markets struggle to underwrite the catastrophic exposure at competitive premiums.
4. Risk 2: Barotrauma and decompression injury
Barotrauma and Decompression — The Dominant Clinical PI Claim
Barotrauma — physical injury resulting from pressure differential during compression or decompression — is the most common clinical complication of HBOT. Recognised forms include auditory barotrauma (perforated tympanic membrane, persistent tinnitus, vertigo, deafness), pulmonary barotrauma (pneumothorax, arterial gas embolism), sinus barotrauma, dental barotrauma, and barotrauma of pre-existing pulmonary blebs or bullae. Incidence rates in clinical HBOT vary by series but auditory barotrauma occurs in a meaningful minority of treatment courses (typically 5–15% depending on patient population). Most cases are minor and self-resolving; a smaller fraction produce persistent injury that engages PI exposure. The 2026 claim pattern increasingly involves: failure to screen for predisposing conditions (recent ear, nose, throat or sinus surgery; untreated otitis media; pulmonary blebs); inadequate ear-clearing technique training; pressure ramp rates not adjusted for patient response; failure to act on patient-reported discomfort during compression.
Pre-treatment screening protocol including documented ear, sinus, dental, and pulmonary review; chest X-ray for clinical HBOT where indicated; patient briefing on equalisation techniques (Valsalva, Toynbee, Frenzel manoeuvres) before first treatment; documented compression and decompression profile aligned to British Hyperbaric Association and European Code of Good Practice; pressure ramp rate adjustment based on patient feedback; chamber operator continuous patient observation; protocols for managing reported discomfort (pause, hold, decompress); post-treatment review documenting any complications; specialist ENT referral pathway documented for any concerning symptoms; consent process including specific written acknowledgement of barotrauma risk.
Professional Indemnity / Medical Malpractice with specific HBOT treatment scope. Generic alternative therapy PI typically may not contemplate barotrauma exposure; specialist placement covers it. Limits typically £1m–£2m for single-chamber wellness operators; £2m–£10m for clinical HBOT centres with NHS contracting exposure. Claims-made basis is standard; run-off cover is important because chronic auditory barotrauma claims can surface months after the originating treatment course. Claim values typically £15k–£80k for documented hearing or vestibular injury; pulmonary barotrauma cases involving pneumothorax or air embolism can reach £100k–£300k+ where neurological sequelae arise.
5. Risk 3: Oxygen toxicity — neurological and pulmonary
Oxygen Toxicity — Rare but Severe
Oxygen toxicity is the systemic injury produced by excessive partial pressure or duration of oxygen exposure. Central nervous system (CNS) toxicity — historically called the Paul Bert effect — manifests as seizures, typically at partial pressures above 1.6 ATA and with prolonged exposure. Pulmonary toxicity — the Lorrain Smith effect — produces tracheobronchitis and reduced vital capacity with prolonged exposure even at lower partial pressures. CNS toxicity in clinical HBOT is uncommon at the typical treatment profile (2.0–2.4 ATA, 90 minutes, "air breaks") but documented; pulmonary toxicity is rare in standard treatment courses. The risk is materially elevated in patients with seizure history, hypercapnia, fever, or certain medications. Wellness mHBOT operating at 1.3–1.5 ATA carries lower toxicity risk but the screening discipline is typically less rigorous, raising relative claim exposure.
Documented screening for seizure history, hypercapnia, hyperthermia, and toxicity-potentiating medications; treatment profile design with "air breaks" (5-minute periods breathing chamber air during prolonged treatments at higher pressure); documented chamber operator observation for CNS toxicity signs (lip twitching, vision changes, tinnitus, nausea, irritability, tachycardia); emergency response protocol for seizure during treatment (depressurisation, removal of oxygen breathing apparatus, supportive care); consent process including specific written acknowledgement of oxygen toxicity risk; chamber operator training including recognition of toxicity prodrome; documented protocols for managing high-risk patients (lower pressure, shorter duration, more frequent air breaks).
Professional Indemnity / Medical Malpractice responding to oxygen toxicity-related claims. CNS toxicity claims involving seizure-related injury (head injury during fall, aspiration, chamber emergency) can be high-severity — £40k–£250k+ depending on outcome. The defence depends on documented screening, treatment profile design, and operator response to prodromal symptoms. Run-off cover important for late-presenting pulmonary toxicity claims.
6. Risk 4: Equipment failure and PUWER breach
Equipment Failure — The Routine Operational Claim
Oxygen therapy equipment — concentrators, cylinders, regulators, compressors, chamber pressure vessels, oxygen masks and BIBS (built-in breathing system), monitoring equipment — is "work equipment" within the meaning of the Provision and Use of Work Equipment Regulations 1998 (PUWER), requiring it to be suitable, safe, maintained, inspected, and operated only by trained competent persons. Hyperbaric chambers are also pressure systems under the Pressure Systems Safety Regulations 2000 with separate written scheme of examination requirements. The routine claim profile is mid-treatment equipment failure: oxygen concentrator output dropping during a treatment; chamber pressurisation system failure during compression; BIBS failure during chamber treatment; oxygen monitoring sensor drift undetected; door seal failure preventing safe completion. Most failures produce minor disruption and modest claims; serious equipment failure can produce barotrauma or interrupted treatment claims well into the £10k–£40k range.
Documented equipment register with serial numbers, install dates, and service history per item; pre-use checks per session documented; periodic servicing per manufacturer schedule; annual statutory inspection for pressure vessels under the Pressure Systems Safety Regulations 2000 (written scheme of examination by competent person); calibration of monitoring equipment per manufacturer schedule; oxygen concentrator periodic output verification; staff trained in operation, fault identification, and emergency response; equipment fault and near-miss reporting system; equipment retirement and replacement protocol where parameters drift; competent person and PSSR records audit-ready.
Public Liability standard response for third-party harm; Equipment / Machinery breakdown cover for the equipment itself; Business Interruption covering revenue loss during equipment downtime. Generic alternative therapy equipment cover may sub-limit pressure vessels and large compressors — specialist placement explicitly schedules these. Cover responds where PUWER and PSSR compliance is documented; absence of those records routinely produces claim difficulty.
7. Risk 5: Inadequate clinical screening and contraindications
Clinical Screening Failure — The Rising PI Risk
HBOT and mHBOT have a defined list of absolute and relative contraindications that demand documented pre-treatment screening. Absolute contraindications include untreated pneumothorax; relative contraindications include severe COPD, recent ear or sinus surgery, certain medications (notably bleomycin, doxorubicin, disulfiram, cisplatin), pregnancy, claustrophobia, and undrained chest infection. Wellness mHBOT centres serving general public patients on a self-referral basis face elevated screening exposure: the patient frequently presents with conditions the operator has neither the clinical training nor the duty to identify. The 2026 claim pattern increasingly involves: failure to identify a relevant contraindication during intake; failure to refer for clinical assessment where indicated; treatment provided despite documented contraindication; inadequate consent process not addressing the specific risks for that patient's profile; failure to monitor and act on patient-reported symptoms suggesting an emerging issue during treatment.
Structured intake questionnaire covering all absolute and relative contraindications; clinical sign-off required for any flagged condition (typically by GP or specialist letter); documented decision rules on which presentations require clinical assessment before treatment; clear pre-treatment medication review for known interactions; consent process tailored to individual patient profile rather than generic template; staff trained to recognise red flags during intake; documented escalation pathway for patients with concerning presentation; periodic case review programme; refusal protocol for patients whose contraindications cannot be safely managed.
Professional Indemnity / Medical Malpractice responding to screening failure claims. Cover responds where structured screening was conducted and documented. Wellness mHBOT operators who explicitly disclaim medical responsibility face cover scope questions — the disclaimer does not eliminate duty of care, and PI underwriters increasingly scrutinise the screening framework regardless of disclaimer language. Specialist placement explicitly addresses screening duty for non-medical-staff operators.
8. Oxygen therapy insurance cover checker
Select your business profile below to see the cover matched to your specific risk profile. For Miller & Partner's main alternative therapies product page see alternative therapies business insurance.
Oxygen Therapy Insurance Cover Checker
Select your business profile to see the recommended insurance programme matched to the 8 main oxygen therapy risks
Oxygen Bar / Oxygen Facial (Ambient)
- ESSENTIAL Public Liability £2m–£5m with treatment risk and oxygen handling specifically declared
- ESSENTIAL Property and Equipment cover for concentrators and cylinders
- ESSENTIAL Documented DSEAR risk assessment in place
- LEGAL Employers' Liability £10m if any staff
- RECOMMENDED Professional Indemnity £250k–£500k if any health claims made about treatments
- RECOMMENDED Business Interruption covering oxygen supply or equipment downtime
- RECOMMENDED Cyber insurance for client records
- CONSIDER Legal Expenses with HSE and Trading Standards scope
Single-Chamber mHBOT Wellness
- CRITICAL Pressurised oxygen-enriched chamber must be specifically declared — generic wellness PL typically inadequate
- ESSENTIAL Public Liability £2m–£5m with explicit fire and treatment risk scope
- ESSENTIAL Professional Indemnity / Medical Malpractice £500k–£1m with barotrauma and screening scope
- ESSENTIAL Property cover with chamber specifically scheduled
- ESSENTIAL Equipment / Machinery cover for chamber and compressor
- ESSENTIAL Business Interruption with chamber dependency assessed
- LEGAL Employers' Liability £10m if any staff
- ESSENTIAL Documented DSEAR and fire risk assessment
- RECOMMENDED Legal Expenses with HSE and CQC scope
Multi-Chamber mHBOT Wellness
- CRITICAL Multiple pressurised chambers materially elevate fire and BI exposure; specialist placement essential
- LEGAL Employers' Liability £10m
- ESSENTIAL Public Liability £5m–£10m with comprehensive treatment risk scope
- ESSENTIAL Professional Indemnity / Medical Malpractice £1m–£2m
- ESSENTIAL Property with all chambers scheduled and oxygen storage specifically declared
- ESSENTIAL Equipment / Machinery comprehensive
- ESSENTIAL Business Interruption with realistic indemnity period (12–24 months)
- ESSENTIAL Environmental Impairment Liability for fire suppression and oxygen leak scenarios
- ESSENTIAL Legal Expenses comprehensive scope including HSE
- ESSENTIAL Cyber insurance for client and clinical records
- ESSENTIAL Directors and Officers (D&O) liability
Clinical HBOT (Private, Hard-Shell)
- CRITICAL Clinical HBOT operates at 2.0–3.0 ATA with maximum fire risk; specialist Lloyd's placement typically required
- LEGAL Employers' Liability £10m
- ESSENTIAL Public Liability £10m with comprehensive treatment risk, fire and explosion scope
- ESSENTIAL Professional Indemnity / Medical Malpractice £5m–£10m with full clinical scope
- ESSENTIAL Property with chamber(s) specifically scheduled at replacement cost
- ESSENTIAL Equipment / Machinery comprehensive
- ESSENTIAL Business Interruption with realistic indemnity period (24 months minimum)
- ESSENTIAL Environmental Impairment Liability
- ESSENTIAL Legal Expenses with HSE, CQC, MHRA, and prosecution defence scope
- ESSENTIAL Cyber insurance comprehensive
- ESSENTIAL Directors and Officers (D&O) liability
- ESSENTIAL CQC registration with all regulated activities correctly declared
NHS-Contracted HBOT Centre
- CRITICAL NHS service specification (Jan 2025 update) specifies minimum cover terms; review against contract requirements
- LEGAL Employers' Liability £10m
- ESSENTIAL Public Liability £10m typically required by NHS contracting
- ESSENTIAL Professional Indemnity / Medical Malpractice £10m typically required
- ESSENTIAL Property comprehensive with chambers scheduled
- ESSENTIAL Business Interruption — NHS contract dependency assessment
- ESSENTIAL Environmental Impairment Liability
- ESSENTIAL Legal Expenses comprehensive — NHS contract dispute, HSE, CQC scope
- ESSENTIAL Cyber comprehensive — NHS data sharing exposure
- ESSENTIAL Directors and Officers (D&O) liability
- ESSENTIAL Specific declaration of NHS commissioned vs private mix at proposal
Sports / Athletic Supplemental Oxygen
- ESSENTIAL Public Liability £2m–£5m with oxygen handling specifically declared
- ESSENTIAL Property and Equipment cover for concentrators and cylinders
- ESSENTIAL Documented DSEAR risk assessment
- LEGAL Employers' Liability £10m if any staff
- RECOMMENDED Professional Indemnity if treatment claims are made or trainer advice given
- RECOMMENDED Personal Accident cover if athletes are not separately insured
- RECOMMENDED Business Interruption
- CONSIDER Sports facility package as base policy with oxygen specifically endorsed
9. Fire safety and compliance self-check
The Troy Michigan precedent and the documented MHRA regulatory gap have together raised the proposal-stage fire safety expectations for UK oxygen therapy operators. Tick each fire safety and compliance discipline your operation has in place. The unchecked items are your priority compliance and insurance gaps.
Fire Safety & Compliance Self-Check
Click each discipline you have in place. The more ticked, the lower your fire and regulatory exposure.
-
Documented DSEAR 2002 risk assessment per location with zone classification (Zone 0/1/2) for oxygen-enriched atmospheres
-
Fire risk assessment per RR(FS)O 2005 with periodic review and named responsible person documented
-
Ignition source elimination protocol — anti-static garments provided, prohibited items list, oil-free maintenance discipline
-
Patient garment-change and items-check procedure documented and applied before every chamber session (cosmetics, hair products, synthetics, electronics)
-
Pressure systems written scheme of examination under PSSR 2000 maintained by competent person for chamber operators
-
PUWER 1998 equipment register with pre-use checks, periodic servicing, and inspection records for all oxygen equipment
-
Emergency depressurisation and fire response procedure documented, displayed, and rehearsed with documented drills
-
Smoke / heat detection and fire-fighting equipment specifically rated for oxygen-enriched and oxygen-fed fires
-
Oxygen storage compliance — secured upright cylinders, ventilated storage, separation from combustibles, hot work permit system
-
Building insurance provider and landlord notified of oxygen chamber and storage installation with documented consent where required
-
CQC registration status confirmed — registration where regulated activity performed; documented rationale where not
-
Insurance specifically declared for the modality operated — written broker confirmation that chamber operation (and pressure profile if HBOT/mHBOT) is within cover scope
10. Oxygen therapy operation risk assessor
Two factors drive oxygen therapy operational risk above all others: the modality operated (ambient oxygen vs mHBOT vs clinical HBOT) and the maturity of fire safety and clinical documentation. Use the tool below for your specific risk profile.
Oxygen Therapy Operation Risk Assessor
Select your modality and your documentation maturity to see your specific risk profile and indicative insurance package
11. Risk 6: MHRA medical device regulatory uncertainty
MHRA Regulatory Gap — The Documented Wellness mHBOT Uncertainty
The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK regulator for medicines and medical devices under the Medical Devices Regulations 2002 and the Medicines and Medical Devices Act 2021. Independent UK clinicians who have publicly engaged with MHRA on hyperbaric chamber regulation have documented that the MHRA does not consider a hyperbaric chamber to be a medical device when it is used by a non-healthcare worker — even when the chamber is being used to provide what the operator describes as a therapeutic treatment. The practical consequence: a wellness mHBOT operator selling treatments to the public, claiming health benefits, but operating without healthcare professional involvement, sits in a documented regulatory grey zone where neither MHRA medical device safety regulation nor (in many cases) CQC registration as a healthcare provider applies.
The insurance implications are practical and significant. PI underwriters faced with claims involving wellness mHBOT operations cannot point to a single coherent regulatory framework governing the activity. Operators marketing health benefits face Trading Standards exposure under the Consumer Protection from Unfair Trading Regulations 2008 and the Advertising Standards Authority (ASA) framework, which has issued multiple rulings against unsubstantiated mHBOT health claims. Operators offering treatment for specific medical conditions risk being deemed to be performing a "regulated activity" under CQC requirements without registration — a criminal offence. The 2026 underwriting position is increasingly to treat wellness mHBOT operators as if they were subject to the clinical framework regardless of formal regulatory status, requiring documented screening, clinical sign-off pathways, and limited health claims.
Marketing review against ASA and CAP code requirements for health claims; substantiation file maintained for any therapeutic claims made; CQC registration position documented (registered as Treatment of Disease, Disorder or Injury where applicable; documented rationale for non-registration where claimed); clinical sign-off pathway for any treatment indication beyond general wellness; medical disclaimer language reviewed and consistent across all marketing channels; complaints handling process documented; trading standards engagement protocol; periodic legal review of regulatory positioning.
Professional Indemnity scope review specifically addressing the regulatory uncertainty of wellness mHBOT — generic PI may exclude treatments not regulated as healthcare; specialist placement explicitly addresses the modality regardless of MHRA status. Legal Expenses with Trading Standards and ASA scope; D&O cover for personal regulatory exposure of directors making marketing decisions; EIL where relevant. The cover responds where operational documentation evidences reasonable steps to navigate the regulatory framework; absence of that documentation routinely produces claim difficulty.
12. Risk 7: HSE prosecution and DSEAR breach
HSE Prosecution — Catastrophic Director Exposure
HSE prosecution of oxygen therapy operators is rare per business but consequential when it occurs. UK Sentencing Guidelines for health and safety offences mean a micro-company (under £2m turnover) can face fines of £150,000–£450,000 even where no injury actually occurred. Section 37 of the Health and Safety at Work Act 1974 enables prosecution of directors personally where the offence was committed with their consent, connivance, or attributable to their neglect — with imprisonment of up to 2 years. The Corporate Manslaughter and Corporate Homicide Act 2007 creates a separate corporate manslaughter offence with unlimited fines and corporate remedial orders. Oxygen therapy-specific prosecution drivers include: chamber fire with patient injury or fatality (engaging DSEAR breach exposure); operative oxygen-related injury from inadequate handling protocols; pressure vessel failure under PSSR 2000; failure to comply with HSE improvement or prohibition notices issued after inspection.
Documented health and safety management system; site-specific DSEAR risk assessment; PUWER and PSSR compliance documented; structured training matrix with renewal dates; near-miss reporting culture; senior management visible engagement with safety (board-level discussion documented); periodic internal audit against HSE expectations; documented response to any HSE improvement notice or inspection finding; competent person engagement for PSSR written scheme.
Legal Expenses insurance with HSE investigation scope provides defence cost cover (criminal fines themselves are uninsurable under UK public policy). Directors and Officers (D&O) liability cover for individual director defence costs in personal prosecutions. The fines remain uninsurable but the defence costs — routinely £50,000–£250,000 for a contested HSE prosecution — are insurable and should be specifically scoped. Specialist Legal Expenses brokers can structure cover specifically for HSE investigation and prosecution exposure.
13. Risk 8: Insurance non-disclosure under the Insurance Act 2015
Insurance Non-Disclosure — The Most Preventable Catastrophe
The most common reason UK insurance claims are reduced or declined isn't underwriting fraud or bad luck — it's non-disclosure at the proposal or renewal stage. Oxygen therapy operators routinely buy alternative therapy, wellness, or beauty package policies without specifically declaring the oxygen modality. Common non-disclosure patterns: pressurised chamber operation not specifically declared on a wellness package policy; chamber pressure profile (atmospheres absolute) not declared; treatment indications and target patient population not declared; soft-shell mHBOT chamber treated as ordinary equipment without recognition of oxygen-enriched atmosphere risk; CQC registration status not declared. The Insurance Act 2015 requires "fair presentation of the risk" — proactively disclosing every material fact the insurer would want to know. Failure to do so allows the insurer to: avoid the policy (treating it as never having existed); reduce the claim proportionally; impose terms that would have applied with proper disclosure.
Annual review of declared activities against actual operations; written confirmation from broker that all current activities are within scope; specific declaration at proposal of each modality (ambient, mHBOT, clinical HBOT), chamber count and type, pressure profile, indications treated, age groups treated, operator qualifications, CQC registration status, fire safety measures; mid-term notifications to broker when new modalities are added; documented response to broker enquiries at renewal; retention of policy documents and broker correspondence as evidence.
There is no insurance response to insurance non-disclosure — that's the whole point. The cover that should have responded doesn't. The only mitigation is at the proposal stage: detailed declaration, broker discipline, and renewal review. Specialist oxygen therapy broker placement makes a material difference here — generic brokers often miss the specific declarations that HBOT and mHBOT operations require, while specialist brokers know exactly what each insurer expects to see at proposal. For more on the broader principle see our business insurance quote guide.
14. What drives the cost of oxygen therapy insurance in 2026?
Oxygen therapy insurance pricing in 2026 reflects the post-2025 fire risk and regulatory transformation. Indicative annual premium ranges:
| Business Profile | Indicative Annual Premium 2026 |
|---|---|
| Oxygen bar / oxygen facial — ambient, £40k–£150k turnover | £1,200–£2,800 |
| Sports / athletic supplemental oxygen, £80k–£250k turnover | £1,500–£3,500 |
| Single-chamber mHBOT wellness, £100k–£300k turnover | £3,500–£8,500 |
| Multi-chamber mHBOT wellness, £300k–£900k turnover | £8,000–£22,000 |
| Clinical HBOT private centre, £500k–£2m+ turnover | £18,000–£55,000 |
| NHS-contracted HBOT centre, £1m–£5m+ turnover | £35,000–£75,000+ |
The factors below drive both insurance premium and overall risk management investment. The differential between modality bands is typically larger than the differential within any single band — meaning modality choice is the dominant rating factor, with documentation maturity the dominant secondary driver.
| Rating Factor | Impact on Premium | What You Can Do |
|---|---|---|
| Modality (ambient vs mHBOT vs clinical HBOT) | Largest single rating factor; clinical HBOT 5–8× ambient | Declare accurately; cannot reduce differential without changing service model |
| Chamber count and pressure profile | Each additional chamber adds proportionally; higher ATA premium uplift | Declare specifically — chamber count, ATA, manufacturer |
| Fire safety documentation maturity | Mature DSEAR/PSSR/PUWER documentation reduces premium 15–25% | Implement comprehensive documentation pack — see self-check tool above |
| Annual treatment volume and turnover | Primary scaling factors for PL, EL, PI | Declare accurately including planned growth |
| Indications treated and target population | Higher-risk indications (paediatric, post-stroke, complex medical) add 20–40% premium | Declare specifically; assess commercial necessity of higher-risk indications |
| Operator clinical qualifications | GMC-registered doctor on site reduces premium 15–25% for clinical HBOT | Document staffing model and clinical oversight arrangements |
| CQC registration status | Registered + Good rating reduces premium 10–20% | Maintain registration; mock inspection programme; respond to findings promptly |
| Limits selected | £2m vs £5m vs £10m PL material; PI limits proportional to caseload | Match to contract requirements and modality exposure |
| Claims history | 5+ year impact; fire and barotrauma claims particularly material | Root cause analysis and remedial documentation after any claim |
| Premises configuration | Standalone premises with fire compartmentation reduces premium; mixed-use buildings add 15–30% | Documented fire compartmentation; landlord and building insurance engagement |
| Broker placement | Specialist oxygen / HBOT brokers access better terms than generic placement | Use a broker with specialist alternative therapies and chamber-based underwriting experience |
| Continuity with insurer | 3+ years with same insurer typically reduces renewal premium 5–10% | Strategic continuity decision; don't chase £500 savings |
15. Real claims and how to manage them
Claim — Chamber Burn / Fire-Adjacent PL, £180,000 Settlement
A multi-chamber mHBOT wellness centre operating four soft-shell single-place chambers experienced a near-fire incident during a session. A client entered her chamber in synthetic clothing (against the centre's documented prohibited items list, but the pre-session check had not been performed that day due to operator pressure). During the session, a static discharge ignited the synthetic fabric in the oxygen-enriched chamber atmosphere; flames were extinguished within seconds by the emergency depressurisation but the client sustained second-degree burns to her torso and one arm. Two adjacent chambers were closed for 11 weeks during HSE investigation; one chamber was deemed unsalvageable due to smoke damage and pressure vessel integrity concerns.
The client brought a PL claim alleging: failure to enforce the documented prohibited items list; failure to perform the documented pre-session check; inadequate operator training and supervision; oxygen-enriched atmosphere not adequately controlled. Settlement: £180,000 (medical costs including reconstructive surgery, lost earnings during 7-month recovery, future medical costs, psychological injury, general damages). Defence costs: £42,000. Total claim: £222,000.
HSE investigation followed. The centre received an improvement notice requiring documented enforcement of the pre-session check and operator supervision arrangements. No prosecution was brought given the absence of injury beyond the client and the centre's cooperative response. Legal costs for HSE engagement: £18,000 — recovered through Legal Expenses insurance.
Post-claim renewal: PL premium increased 65%; Property premium increased 40% (one chamber written off plus elevated risk rating). Insurer required: structured pre-session check enforced and documented; CCTV monitoring of chamber entry area; daily operator briefing and signed-off prohibited items list; quarterly fire drill with chamber emergency depressurisation rehearsed; building fire safety review with separation between chambers improved. The centre implemented these and at the following renewal premium returned to a 28% loading over baseline.
The lesson: even a near-fire incident with single-client injury produces six-figure claims for mHBOT operators. The £180k claim was a fraction of what the Troy Michigan-equivalent fatal incident would have engaged. The documentation discipline that prevents these incidents — pre-session check enforcement, prohibited items list, operator supervision — is the same documentation that defends the claim when one occurs. Generic wellness PL frequently doesn't contemplate oxygen-enriched fire-adjacent incidents; specialist placement covers it.
Claim — Barotrauma PI, £58,000 Settlement
A single-chamber mHBOT wellness operator treated a 42-year-old self-referred client over a 10-session course at 1.5 ATA. The client's intake form had noted "recent ear infection" which the operator had marked as resolved without further clinical review. During session 3, the client reported significant ear discomfort during compression. The operator continued the session at the client's request. By session 5, the client reported persistent tinnitus and reduced hearing in one ear. ENT specialist assessment confirmed tympanic membrane scarring, persistent unilateral tinnitus, and 25% hearing loss in the affected ear deemed unlikely to recover.
The client brought a PI claim alleging: failure to obtain GP clearance for the recent ear infection (a relative contraindication that should have been verified); failure to act on the patient-reported discomfort during compression at session 3; failure to refer to ENT specialist at session 5 when symptoms persisted; inadequate consent process not addressing barotrauma risk specifically.
The operator's PI responded. Settlement: £58,000 (medical costs, future audiology care, ongoing tinnitus management, lost earnings during initial treatment period, general damages for permanent hearing impairment). Defence costs: £14,800. Total claim: £72,800.
Post-claim renewal: PI premium increased 50%. Insurer required: structured intake protocol with documented clinical sign-off for any flagged condition; pause-and-escalate protocol for any patient-reported discomfort during compression; documented ENT referral pathway; consent process tailored to individual contraindications. The operator implemented these and at the following renewal premium returned to a 25% loading over baseline.
The lesson: barotrauma is the dominant clinical PI claim category for mHBOT operators. The documentation that defends these claims — structured intake, escalation protocols, ENT referral pathway — is the same documentation that prevents them. Wellness operators frequently rely on intake forms without clinical sign-off; the post-2025 PI environment increasingly requires that pathway to be explicit and documented.
Claim — Equipment Failure with Business Interruption, £42,000 Combined
A single-chamber mHBOT wellness operator experienced sudden chamber air compressor failure mid-session. The chamber depressurised in a controlled manner per safety protocol with no patient injury. Subsequent investigation found the compressor had failed due to undetected progressive wear on the cylinder seal — the operator had been performing pre-session checks but had not conducted the manufacturer-specified 6-month service for the previous 14 months. The chamber was unusable for 9 weeks pending compressor replacement and re-certification of the pressure system under PSSR 2000.
Costs: replacement compressor and installation £8,500; PSSR re-certification by competent person £2,200; revenue loss over 9 weeks of chamber downtime £24,000; additional staff costs maintaining other operations during chamber closure £4,800; client refunds and credits £2,500. Total: £42,000.
The operator claimed under Equipment / Machinery breakdown cover and Business Interruption. The claim was initially disputed by the insurer on the grounds that the manufacturer-specified service had not been performed, potentially breaching the PUWER condition in the policy. Settlement was eventually reached at a 25% claim reduction (£31,500 paid against £42,000 claimed) on the basis that the failure mode was not solely attributable to the missed service.
Post-claim renewal: Equipment premium increased 30%; BI premium increased 20%. Insurer required: documented service schedule per manufacturer specification; signed-off service records for every interval; PSSR written scheme of examination current with named competent person; pre-session check log audit-trail. The operator implemented these and at the following renewal premium returned to a 12% loading over baseline.
The lesson: equipment failure is the routine operational claim category but PUWER and PSSR compliance gaps make claim recovery uncertain. The documentation discipline costs little to maintain and is the difference between full claim payment and a 25%+ reduction. The £10,500 claim reduction in this case would have funded several years of proper service contracts.
Claims Management Steps
How to respond to an oxygen therapy incident, claim, or regulatory engagement — the steps below are critical given the multi-policy and multi-regulator exposure typical of 2026 oxygen therapy operations:
- Prioritise patient and staff safety first. For fire or near-fire incidents, ensure complete evacuation, emergency services on scene, and medical care for any affected persons before any administrative response begins. For chamber emergencies, follow the documented depressurisation protocol.
- Notify your insurer immediately for any potential claim. Oxygen therapy incidents often engage multiple policies (PL, PI/Medical Malpractice, Property, BI, EIL, Legal Expenses, D&O). Single notification triggers coordinated response. Threshold is "may give rise to a claim" — much lower than "formal claim received".
- Preserve all documentation rigorously. DSEAR risk assessment; fire risk assessment; PSSR written scheme of examination; PUWER equipment records; pre-session check logs; patient intake and consent forms; clinical screening documentation; operator training records; chamber operator logs; CCTV footage where available. The documentation pack is the defence across all coverage layers.
- Do not admit liability or fault. Provide factual information about what happened, what protocol was followed, what evidence was available at the time. Do not accept fault or apologise in writing in a way that could be interpreted as admission. The duty of candour applies for clinical incidents but is distinct from liability admission.
- Manage HSE / CQC / MHRA engagement carefully. If regulators attend or notify, engage your Legal Expenses insurer immediately. Cooperate factually with inspectors but do not provide written statements without legal representation. HSE investigation of fire incidents can become criminal prosecution under DSEAR and HSAW 1974 Section 37.
- Notify CQC under regulatory reporting duties where applicable. Under the Health and Social Care Act 2008 (Regulated Activities) Regulations 2014, certain incidents are notifiable to CQC within specified timeframes including deaths, serious injuries, and allegations of abuse. RIDDOR reporting also applies for workplace injuries.
- Conduct root cause analysis and document remedial action. Identify underlying cause and implement remedial action. Insurers reviewing renewal will ask what's changed since claim; HSE and CQC will require evidence of remedial action; the duty of candour requires honest disclosure to affected patients where applicable.
- Update operational documentation to address gap. Where the claim identified a documentation gap (no DSEAR assessment, no pre-session check enforcement, no PUWER service record, no clinical screening), update the standard operating procedure to close the gap going forward. This is both insurance and regulatory defence.
Glossary of oxygen therapy insurance terms
- HBOT (Hyperbaric Oxygen Therapy)
- Treatment in which a patient breathes 100% oxygen inside a pressurised chamber at 2.0–3.0 atmospheres absolute. Used clinically for indications including decompression illness, carbon monoxide poisoning, late radiation tissue injury, and problem wounds.
- mHBOT (Mild Hyperbaric Oxygen Therapy)
- Lower-pressure treatment (typically 1.3–1.5 ATA) in soft-shell inflatable chambers, primarily offered in wellness, athletic recovery, and longevity contexts. Clinical evidence for general wellness applications is contested.
- ATA (Atmospheres Absolute)
- The unit of pressure measurement used in hyperbaric medicine. 1 ATA equals sea-level atmospheric pressure; clinical HBOT typically operates at 2.0–3.0 ATA; mHBOT typically operates at 1.3–1.5 ATA.
- Barotrauma
- Physical injury caused by pressure differential during compression or decompression. Common forms include auditory barotrauma (ear injury), pulmonary barotrauma (lung injury, pneumothorax), sinus and dental barotrauma.
- Oxygen Toxicity
- Systemic injury from excessive partial pressure or duration of oxygen exposure. CNS toxicity (the Paul Bert effect) manifests as seizures; pulmonary toxicity (the Lorrain Smith effect) manifests as tracheobronchitis and reduced vital capacity.
- DSEAR (Dangerous Substances and Explosive Atmospheres Regulations 2002)
- UK regulations governing risks from dangerous substances and potentially explosive atmospheres. Oxygen-enriched atmospheres are classified as dangerous substances under DSEAR, requiring risk assessment, zone classification, and explosion protection measures.
- PSSR (Pressure Systems Safety Regulations 2000)
- UK regulations governing the safe operation of pressure systems including hyperbaric chambers. Require a written scheme of examination prepared by a competent person, periodic examination, and documented operator training.
- PUWER (Provision and Use of Work Equipment Regulations 1998)
- UK regulations requiring work equipment to be suitable, safe, maintained, inspected, and operated only by trained competent persons. Apply to all oxygen therapy equipment including chambers, concentrators, and cylinders.
- BIBS (Built-In Breathing System)
- The oxygen delivery system inside a multiplace hyperbaric chamber that supplies pure oxygen to individual patients via demand-regulated masks while the chamber atmosphere itself remains air. Reduces fire risk vs full chamber oxygen pressurisation.
- BS EN 14931
- The British/European Standard for "Pressure vessels for human occupancy (PVHO) — Multiplace pressure chamber systems for hyperbaric therapy". Governs the construction and safety of clinical hyperbaric chambers.
- MHRA (Medicines and Healthcare products Regulatory Agency)
- The UK regulator for medicines and medical devices. MHRA does not classify hyperbaric chambers as medical devices when operated by non-healthcare workers, creating a documented regulatory grey zone for wellness mHBOT.
- CQC (Care Quality Commission)
- The independent regulator of health and social care in England. Required for any provider undertaking regulated activities including treatment of disease, disorder or injury. Equivalent regulators apply in Scotland (HIS), Wales (HIW), and Northern Ireland (RQIA).
- BHA (British Hyperbaric Association)
- The UK professional body for hyperbaric medicine. Publishes safety standards, training requirements, and clinical guidance for hyperbaric chamber operation. BHA-aligned methodology is the working insurance standard for clinical HBOT.
- RR(FS)O (Regulatory Reform (Fire Safety) Order 2005)
- The principal UK fire safety legislation. Places duties on the "responsible person" at any premises to conduct fire risk assessment, take fire safety measures, and provide information and training.
- Right to Choose
- NHS Patient Choice regulations in England that enable patients to opt for a specific service or provider. Some clinical HBOT centres operate under Right to Choose contracts as well as fully private services.
- Run-off Cover
- Professional Indemnity cover that continues to respond to claims notified after the policy has ended, provided the work was performed during the original policy period. Essential for barotrauma claims that can surface months or years after treatment.
Frequently asked questions
Oxygen therapy business insurance is specialist commercial insurance designed for operators of ambient oxygen services (oxygen bars and facials), mild hyperbaric oxygen therapy (mHBOT) wellness centres, clinical hyperbaric oxygen therapy (HBOT) centres, and supplemental oxygen services for athletes. The core covers in 2026 are: Public Liability with explicit fire and treatment risk scope; Professional Indemnity / Medical Malpractice with barotrauma, oxygen toxicity, and screening scope; Property and Equipment with chambers and oxygen storage specifically scheduled; Business Interruption; Environmental Impairment Liability; Legal Expenses with HSE, CQC, and MHRA scope; Cyber where clinical records are held. Cover differs fundamentally from generic alternative therapy packages — those typically don't contemplate oxygen-enriched fire risk or pressurised chamber barotrauma exposure.
The 31 January 2025 fatal fire at the Oxford Center in Troy, Michigan, in which a 5-year-old boy died inside a monoplace hyperbaric chamber and his mother was injured, is the working international precedent for hyperbaric fire risk in 2026. UK underwriters paid close attention. The downstream effect: catastrophic fire scope on PL has tightened with explicit fire and explosion treatment; proposal-stage demand for documented DSEAR risk assessment and ignition source controls; specialist Lloyd's market placement increasingly necessary for clinical HBOT operators because mainstream package markets struggle to underwrite the catastrophic exposure; and PI scope expanded to address screening exposure given the demographic mix in mHBOT services.
Indicative 2026 annual premiums: oxygen bar / facial £1,200–£2,800; sports supplemental oxygen £1,500–£3,500; single-chamber mHBOT wellness £3,500–£8,500; multi-chamber mHBOT wellness £8,000–£22,000; clinical HBOT private centre £18,000–£55,000; NHS-contracted HBOT centre £35,000–£75,000+. Pricing depends on modality (largest single factor — clinical HBOT 5–8× equivalent-turnover ambient), chamber count and pressure profile, documentation maturity, claims history, limits, and broker placement. The differential between modality bands is larger than the differential within any single band. For broader chamber-based treatment pricing principles see our cryotherapy business insurance guide.
Employers' Liability is legally required if you have staff under the Employers' Liability (Compulsory Insurance) Act 1969. CQC registration is required for any provider undertaking regulated activities (clinical HBOT for medical conditions) and registration requires insurance evidence. Public Liability is not legally required but is contractually required by most premises landlords, NHS contracting, and commercial relationships. PUWER, DSEAR, and PSSR regulatory compliance is legally required regardless of insurance status. Other covers (PI, Property, BI, EIL, Legal Expenses, D&O, Cyber) are commercially essential for chamber-based operations but not legally required.
Clinical HBOT operates at 2.0–3.0 ATA in hard-shell chambers under CQC registration with medical staffing and treats defined clinical indications; the underwriting market is specialist Lloyd's-led with PI £5m–£10m, PL £10m, and comprehensive property/BI. Wellness mHBOT operates at 1.3–1.5 ATA in soft-shell chambers typically without CQC registration, often without medical staffing, for general wellness indications; the underwriting market is more accessible but specialist placement is still essential because generic wellness PL doesn't contemplate oxygen-enriched chamber fire or barotrauma risk. The two modalities should never share a generic policy — the risk profiles are too different. Specific declaration of modality, chamber type, ATA, and indications is essential at proposal.
Only if specifically scoped. Generic alternative therapy or wellness PL may exclude or sub-limit oxygen-enriched atmosphere fire incidents — the Troy Michigan-equivalent catastrophic exposure isn't priced into a wellness package premium. Specialist oxygen therapy PL should explicitly cover fire and explosion incidents in the chamber environment; Property should schedule chambers at full replacement value; Business Interruption should reflect the realistic 12–24 month chamber unavailability post-incident. Get written broker confirmation that chamber fire is within scope. The premium uplift for explicit scope is material but the claim exposure without it is potentially business-ending — a chamber fire fatality can engage £1m–£5m+ in combined PL, property, BI, and legal costs.
Required for any provider undertaking regulated activities — typically Treatment of Disease, Disorder or Injury where HBOT is offered for specific medical conditions by healthcare professionals. Equivalent regulator registration applies in Scotland (Healthcare Improvement Scotland), Wales (Healthcare Inspectorate Wales), and Northern Ireland (RQIA). Wellness mHBOT operators marketing general wellness rather than treating medical conditions, and operating without healthcare professional staff, sit in a documented regulatory grey zone — CQC registration may not be required but operating with health claims while unregistered carries Trading Standards and ASA exposure. The CQC will sometimes engage on enforcement action where mHBOT operators are deemed to be performing regulated activities without registration. Get specific legal advice on CQC position before launching mHBOT operations.
Insurance non-disclosure under the Insurance Act 2015. The pattern: operator buys a wellness or beauty package describing the business as "alternative therapy clinic", undertakes mHBOT or HBOT with pressurised chamber operation as a substantial part of the work, doesn't specifically declare the chamber operation and pressure profile. At claim stage, the insurer points to the proposal documentation and questions whether the chamber-specific exposures were within cover scope. Not fraud; normal operation of UK insurance law requiring fair presentation of risk. The fix at proposal stage is minimal cost — specific declaration of modality, chamber type, ATA, indications, and CQC position with written broker confirmation; the retrospective cost is potentially every uninsured claim across multiple policy years.
The single biggest premium reduction lever is documented fire and compliance discipline: DSEAR risk assessment, fire risk assessment per RR(FS)O 2005, PSSR written scheme of examination, PUWER equipment register, ignition source controls, prohibited items enforcement, emergency response drills. Mature documentation typically reduces premium 15–25% across the programme. Other levers: GMC-registered clinical oversight (for clinical HBOT); CQC registration with Good rating; accurate modality and indication declaration; limits matched to actual exposure; 3+ years continuity with same insurer; annual payment vs monthly; specialist broker placement. Stack the levers; don't choose between them. Avoid the trap of buying the cheapest generic wellness package — the saving is dwarfed by uninsured claim exposure under the post-2025 framework.
Yes, where scoped correctly. Professional Indemnity / Medical Malpractice with explicit HBOT or mHBOT treatment scope responds to barotrauma claims — auditory, pulmonary, sinus, dental, and pre-existing pulmonary bleb barotrauma. Generic alternative therapy PI typically doesn't contemplate barotrauma specifically; specialist placement explicitly covers it. The cover responds where structured pre-treatment screening was conducted and documented, where compression and decompression profiles were appropriate, and where patient-reported discomfort was acted upon. Claim values typically £15k–£80k for auditory barotrauma with documented hearing or vestibular injury; pulmonary barotrauma cases involving pneumothorax or air embolism can reach £100k–£300k+. Run-off cover is important — chronic barotrauma claims can surface months or years after treatment.
NHS contracting under the updated January 2025 service specification typically specifies minimum cover terms aligned to the clinical exposure of NHS-funded services. Typical specifications: Public Liability £10m; Professional Indemnity / Medical Malpractice £10m; Employers' Liability £10m; Property at full replacement value with chambers scheduled; Business Interruption with realistic indemnity period (24 months); Environmental Impairment Liability; Cyber comprehensive. Beyond insurance specifically, NHS commissioners require: CQC registration current and rated at least Good; clinical governance demonstrated; BHA-aligned protocols; trained hyperbaric medicine staff; PSSR compliance. The cover specifications are typically minimums; commercial wisdom is to exceed them. For clinical governance principles see our professional indemnity insurance guide.
Look for brokers with specific experience in private healthcare, hyperbaric medicine, and chamber-based treatment risk evidenced by: specialist articles or guides on HBOT and mHBOT insurance and post-2025 cover scope; willingness to discuss specific exposures (chamber fire, barotrauma, oxygen toxicity, MHRA regulatory gap, DSEAR compliance) in detail; access to Lloyd's market and specialist healthcare insurers rather than just mainstream commercial markets; FCA authorisation and documented track record; understanding of clinical HBOT vs wellness mHBOT trade-offs. Avoid brokers offering "alternative therapy package" without discussing oxygen specifics; brokers who can only quote one or two markets; brokers who don't ask about chamber type, ATA, indications, and CQC position at proposal. Miller & Partner specialise in this sector — see our alternative therapies main product page and broader alternative therapies insights hub.
Instagram
LinkedIn